VideoHIVViral Hepatitis and Liver DiseaseLow-level viremia is associated with lower cumulative adherence to antiretroviral therapy in persons with HIVView Video
VideoHIVViral Hepatitis and Liver DiseaseSmall Molecules and mAbs as Antiviral Therapy for COVID-19View Video
VideoHIVViral Hepatitis and Liver DiseasePharmacologically Focused to Optimize HIV Prevention for Transgender WomenView Video
VideoHIVViral Hepatitis and Liver DiseaseImmune Checkpoint Inhibitors in the Treatment of HBVView Video
VideoHIVViral Hepatitis and Liver DiseasePharmacological Considerations for Special PopulationsView Video
VideoHIVViral Hepatitis and Liver DiseaseSpecial Populations Including End Organ Failure: Focus on Long-Acting Cabotegravir and RilpivirineView Video
VideoHIVViral Hepatitis and Liver DiseaseLA Controversies: Need for Oral Lead-In and How to Cover Tail of Injectable LA RegimensView Video
VideoHIVViral Hepatitis and Liver DiseaseApplications and Challenges of ML and AI for PharmacogenomicsView Video
VideoHIVViral Hepatitis and Liver DiseaseTransporters Expression in Brain and Other Tissues I Session: John Gerber Memorial LectureView Video
VideoHIVViral Hepatitis and Liver DiseaseUsing PBPK modelling to estimate lamivudine exposure in children with abnormal kidney functionView Video
VideoHIVViral Hepatitis and Liver DiseaseLow-level viremia is associated with lower cumulative adherence to antiretroviral therapy in persons with HIVView Video
